Evotec SE
Evotec SE (EVO) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
evo · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Evotec SE (EVO) measures how much investors pay for each dollar of the company's trailing earnings. EVO's current PE ratio of N/A is calculated by dividing its stock price of $2.85 by its TTM earnings per share of -$1.09.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 10 fiscal years · Front-end computedMinQ1 · 25%60.7x
MedianQ3 · 75%735.4x
Max
At N/A, EVO's current P/E is lower than in 0% of its annual fiscal year readings over the past 10 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Drug Manufacturers - Specialty & Generic · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Evotec SEYou EVO | $1.0B | N/A | — | -$1.09 |
 Alvotech ALVO | $1.2B | 51.30x | -52.3% | $0.10 |
 Azenta, Inc. AZTA | $1.1B | N/A | — | -$1.22 |
 Harrow Health, Inc. HROW | $1.2B | N/A | — | -$0.14 |
 NovoCure Limited NVCR | $2.0B | N/A | — | -$1.22 |
 Pacira BioSciences, Inc. PCRX | $900M | 163.97x | +52.3% | $0.16 |
 Pharvaris N.V. PHVS | $2.2B | N/A | — | -$2.97 |
Industry Average 2 peers with valid PE | — | 107.64x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-0.28 | — | |
2024-12-31 FY2024 | — | $-0.55 | — | |
2023-12-31 FY2023 | — | $-0.24 | — | |
2022-12-31 FY2022 | — | $-0.50 | — | |
2021-12-31 FY2021 | 32.25x | $0.65 | -95.6% | |
2020-12-31 FY2020 | 735.40x | $0.02 | +717.8% | |
2019-12-31 FY2019 | 89.93x | $0.13 | +195.5% | |
2018-12-31 FY2018 | 30.44x | $0.29 | -62.7% | |
2017-12-31 FY2017 | 81.57x | $0.08 | +129.4% | |
2016-12-31 FY2016 | 35.56x | $0.10 | +7.2% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Evotec SE (EVO) measures how much investors pay for each dollar of the company's trailing earnings. EVO's current PE ratio of N/A is calculated by dividing its stock price of $2.85 by its TTM earnings per share of -$1.09.
Frequently asked questions
EVO pe ratio · 6 questionsEVO's current PE ratio is N/A as of 2026-06-08, based on a stock price of $2.85 and TTM EPS of -$1.09. Data sourced from Financial Modeling Prep via EVO's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Evotec SE SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08